STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (SMFR) (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results